Advertisement

Satranidazole and My Pharmaceutical Research Odyssey: A Success Story

  • Prati Pal Singh
Chapter

Abstract

The start of my nearly 40 yearlong pharmaceutical research odyssey almost coincides with the beginning of my association with Hindustan Ciba-Geigy Limited, Research Centre, Goregaon, Bombay (now Mumbai), and satranidazole. Satranidazole, an excellent and relatively superior molecule, is the first and the only antiamoebic drug that has been discovered, developed and marketed from India. In future, it may find therapeutic applications for many more indications. It is a product of long-drawn, very expensive and intense scientific and technological efforts, often marred with uncertainties and serendipity, of the dedicated scientists and technicians. Satranidazole had to survive spates of several squabbles but, in the end, has emerged as a champion and seen the light of day. Satranidazole will definitely go a long way to improve and invigorate the quality of human life. Nonetheless, for the new and budding drug researchers, the success story of satranidazole, full of different hues and shades of human complexities, will be a source of distinctive inspiration and has several important lessons to offer.

Keywords

Amoebiasis Antiamoebic drugs Ciba-Geigy Entamoeba cricetti Entamoeba histolytica Entamoeba muris Experimental models Luminal Satranidazole 

Notes

Acknowledgements

I thank Dr. K. Nagarajan for the encouragement and generously providing some pictures and documents of archival importance related to satranidazole.

References

  1. CIBA to mark 25 years here with program (1962) The summit herald and summit record. May 24, 1962, Summit N. JGoogle Scholar
  2. Nagarajan K, Arya VP, George T, Sudarsanam V, Shah RK, Goud N, Shenoy SJ, Kulkarni VS, Rao MK (1982) Nitroimidazole part 4.1-[methyl-5-nitroimidazolyl(2)]-2-oxo-3-sulphonyl (carbamoyl-thicarbamoyl) tetrahydroimidzoles. Ind. J Chemother 21B:928–940Google Scholar
  3. Singh PP, Sharma VP (2014) Water and Health. pp i–xxiii + 404, Springer India. ISBN: 978-81-322-1028-3 (Print) 978-81-322-1029-0 (Online);  https://doi.org/10.1007/978-81-322-1029-0 Google Scholar
  4. Singh PP, Tendulkar JS, Nagarajan K (1985) Amoebicidal activity of CG-10213 GO and other nitroimidazoles against axenically grown Entamoeba histolytica. Ind J Parasit 9:99–100Google Scholar
  5. Singh PP, Srivastava VB, Talwalkar S (1987) Natural Entamoeba muris infection in rats: a new model for screening potential luminal amoebicides. Ind J Parasit 11:15–20Google Scholar
  6. Subrahmanyam D, Radhakrishna V (1985) Symposium of the proceedings of the symposium on recent advances in protozoan diseasesGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Prati Pal Singh
    • 1
  1. 1.Centre of Infectious Diseases, Department of Pharmacology and ToxicologyNational Institute of Pharmaceutical Education and ResearchS. A. S. NagarIndia

Personalised recommendations